Ticho Barry 4

What Happened
Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), was granted a total of 100,000 derivative equity awards on February 17, 2026: a 60,000-share option award and a 40,000-share restricted stock unit (RSU) award. Both awards are reported as granted at $0 (i.e., non-cash compensation awards rather than open-market purchases or sales).

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (appears to be within the two-business-day reporting window).
• Awards: 60,000 (option-type award) and 40,000 RSUs; acquisition price reported as $0.
• Vesting (per footnotes):
  • Options: vest 1/48 of total on March 15, 2026, then 1/48 each monthly anniversary thereafter (monthly vesting).
  • RSUs: vest 1/4 annually with first tranche on February 15, 2027 (annual cliff vesting).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing type: Grant/Award (transaction code A). No 10b5-1 plan, tax-withholding sale, or other sale/exercise noted in the excerpt.

Context
These are compensation grants (derivative awards) rather than purchases or sales; options give the right to buy shares subject to a vesting schedule, and RSUs convert to shares upon settlement after vesting. Such awards are routine for executives and reflect company compensation, not immediate insider buying or selling.